This is a must-read for anyone new to this board.
BioCurex and Abbott Jointly Present RECAF Results at International Cancer Congress
RICHMOND, British Columbia, September 24, 2007 -- today announced two presentations to the International Society for Oncodevelopmental Biology and Medicine (ISOBM). The presentations document two RECAF studies involving joint initiatives with the University of Munich, Germany and Abbott.
The first presentation entitled “CHEMILUMINESCENT ASSAY (CIA) FOR THE RECEPTOR OF ALPHA FETOPROTEIN (RECAF) TO SEPARATE CANCER FROM NORMAL SERA” demonstrated the results obtained with the assay format used in several automated instruments including the Abbott ArchitectTM. 68 breast, gastric and other types of cancers were compared to 52 normal patients and the AUC scoring obtained was 0.954 (a perfect discrimination between cancer and normal samples has a score of 1.0). Similar results were independently obtained in Abbott’s facility for prostate cancer samples.
The second study was done in collaboration with Abbott and the University of Munich to determine the best type of specimen collecting tube for RECAF testing in a clinical laboratory environment. There is an extensive variety of blood collecting tubes available. These are vacuum tubes that contain different combinations of chemicals intended to accelerate clotting in various ways, prevent clotting, separate the clot from the serum, etc. Some of them are not compatible with certain assays and therefore it is always necessary before the commercialization of a serum test to find out which tubes are chemically compatible. The results presented indicate that the RECAF assay is compatible with the most commonly used serum collection tube types.
Ricardo Moro, President and CEO stated: "These presentations to the ISOBM validate our joint efforts to develop the RECAF assay in the chemoluminescence format used by high throughput automated instruments. These results correlate with those in previous presentations and provide additional support for the effectiveness of the RECAF technology. This presentation will, no doubt, trigger a positive response from the scientific community and demonstrates to our shareholders that we are steadily progressing toward the commercialization of the technology. Developing the foundations of a test that has the potential to significantly change the way we diagnose cancer takes time and focus. The team effort with Abbott has resulted in very significant progress - part of which was presented at the ISOBM congress. We are getting closer and closer to the commercialization of a cancer test that has the potential to be used for screening patients in much the same way a blood sugar or cholesterol reading is requested as part of a routine blood test. This is extremely valuable, both from the medical as well as the commercial point of view.”
